Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,842 shares of the pharmaceutical company's stock after selling 719 shares during the quarter. Gateway Investment Advisers LLC's holdings in Vertex Pharmaceuticals were worth $26,515,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. grew its position in shares of Vertex Pharmaceuticals by 7.3% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 8,126 shares of the pharmaceutical company's stock worth $3,272,000 after purchasing an additional 554 shares in the last quarter. RMR Wealth Builders boosted its stake in Vertex Pharmaceuticals by 9.0% in the 4th quarter. RMR Wealth Builders now owns 4,239 shares of the pharmaceutical company's stock worth $1,707,000 after purchasing an additional 351 shares during the period. Redhawk Wealth Advisors Inc. grew its holdings in Vertex Pharmaceuticals by 3.0% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 5,339 shares of the pharmaceutical company's stock valued at $2,150,000 after buying an additional 153 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. raised its position in shares of Vertex Pharmaceuticals by 61.4% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,769 shares of the pharmaceutical company's stock valued at $712,000 after buying an additional 673 shares during the last quarter. Finally, Park Avenue Securities LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.3% in the fourth quarter. Park Avenue Securities LLC now owns 14,454 shares of the pharmaceutical company's stock worth $5,821,000 after buying an additional 467 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on VRTX shares. Oppenheimer cut shares of Vertex Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 19th. Canaccord Genuity Group boosted their target price on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a "sell" rating in a research report on Wednesday, November 6th. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and increased their target price for the company from $500.00 to $550.00 in a research note on Monday, December 9th. StockNews.com cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 21st. Finally, Truist Financial reduced their price objective on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a "buy" rating on the stock in a research report on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $490.38.

Vertex Pharmaceuticals Stock Up 1.2 %

VRTX stock traded up $5.04 during trading on Friday, hitting $422.00. 1,771,827 shares of the company's stock traded hands, compared to its average volume of 1,548,989. The firm has a market capitalization of $108.68 billion, a P/E ratio of -212.06, a PEG ratio of 2.11 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $442.83 and a two-hundred day simple moving average of $466.48.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business's revenue was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $3.67 EPS. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.